Anqi Ma

2.7k total citations
31 papers, 1.3k citations indexed

About

Anqi Ma is a scholar working on Molecular Biology, Hematology and Cancer Research. According to data from OpenAlex, Anqi Ma has authored 31 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 5 papers in Hematology and 5 papers in Cancer Research. Recurrent topics in Anqi Ma's work include Epigenetics and DNA Methylation (20 papers), Histone Deacetylase Inhibitors Research (12 papers) and Protein Degradation and Inhibitors (9 papers). Anqi Ma is often cited by papers focused on Epigenetics and DNA Methylation (20 papers), Histone Deacetylase Inhibitors Research (12 papers) and Protein Degradation and Inhibitors (9 papers). Anqi Ma collaborates with scholars based in United States, Canada and Sweden. Anqi Ma's co-authors include Jian Jin, Masoud Vedadi, Fengling Li, Peter J. Brown, Ling Cai, Kwang‐Su Park, Gang Greg Wang, C.H. Arrowsmith, David F. Allison and Stephen V. Frye and has published in prestigious journals such as Nature Communications, Blood and PLoS ONE.

In The Last Decade

Anqi Ma

31 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anqi Ma United States	20	1.2k	200	180	159	68	31	1.3k
Shengyan Xiang United States	16	765 0.6×	134 0.7×	109 0.6×	273 1.7×	69 1.0×	25	919
Neil MacLean Canada	17	588 0.5×	167 0.8×	155 0.9×	253 1.6×	68 1.0×	38	816
Isabella Pallavicini Italy	16	715 0.6×	232 1.2×	291 1.6×	273 1.7×	61 0.9×	20	1.0k
Grace R. Anderson United States	11	573 0.5×	123 0.6×	210 1.2×	190 1.2×	63 0.9×	13	763
Christina J. Allain United States	9	1.3k 1.1×	200 1.0×	89 0.5×	137 0.9×	85 1.3×	10	1.4k
Luis A. Carvajal United States	10	550 0.5×	92 0.5×	134 0.7×	354 2.2×	49 0.7×	29	814
Marta Sánchez-Martín United States	12	553 0.5×	241 1.2×	177 1.0×	224 1.4×	33 0.5×	15	960
Víctor J. Sánchez‐Arévalo Lobo Spain	14	693 0.6×	65 0.3×	152 0.8×	311 2.0×	44 0.6×	23	887
Katja Parapatics Austria	14	762 0.6×	89 0.4×	86 0.5×	195 1.2×	49 0.7×	18	962
Yi Hua Qiu United States	18	974 0.8×	633 3.2×	164 0.9×	236 1.5×	49 0.7×	38	1.4k

Countries citing papers authored by Anqi Ma

Since Specialization

Citations

This map shows the geographic impact of Anqi Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anqi Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anqi Ma more than expected).

Fields of papers citing papers by Anqi Ma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anqi Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anqi Ma. The network helps show where Anqi Ma may publish in the future.

Co-authorship network of co-authors of Anqi Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Anqi Ma. A scholar is included among the top collaborators of Anqi Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anqi Ma. Anqi Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ma, Anqi, et al.. (2024). Atomic molecular dynamics simulation advances of de novo-designed proteins. Quarterly Reviews of Biophysics. 57. e14–e14. 2 indexed citations

Yu, Xufen, Jun Wang, Weida Gong, et al.. (2023). Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. Oncogene. 42(13). 994–1009. 16 indexed citations

Vasquez, Louella, Paul Theodor Pyl, Anqi Ma, et al.. (2023). <i>PVT1</i> interacts with polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma. Haematologica. 109(2). 567–577. 7 indexed citations

Dale, Brandon, Kwang‐Su Park, H. Ümit Kanıskan, et al.. (2022). Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2. ACS Pharmacology & Translational Science. 5(7). 491–507. 32 indexed citations

Wang, Jun, Xufen Yu, Weida Gong, et al.. (2022). EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis. Nature Cell Biology. 24(3). 384–399. 119 indexed citations

Haglöf, Jakob, Elke De Bruyne, Eline Menu, et al.. (2021). A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma. Cell Death and Disease. 12(2). 167–167. 16 indexed citations

Herviou, Laurie, Sara Ovejero, Claire Gourzonès, et al.. (2021). Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma. Clinical Epigenetics. 13(1). 174–174. 19 indexed citations

Xiao, Bin, Anqi Ma, Xiaojun Xu, et al.. (2020). Naprapathy attenuates neuropathic pain after brachial plexus injury. Annals of Palliative Medicine. 9(3). 766–773. 3 indexed citations

Clarke, Thomas L., Ran Tang, Damayanti Chakraborty, et al.. (2019). Histone Lysine Methylation Dynamics Control EGFR DNA Copy-Number Amplification. Cancer Discovery. 10(2). 306–325. 39 indexed citations

10.

Ma, Anqi, Ηλίας Στρατικόπουλος, Kwang‐Su Park, et al.. (2019). Discovery of a first-in-class EZH2 selective degrader. Nature Chemical Biology. 16(2). 214–222. 167 indexed citations

11.

Lima‐Fernandes, Evelyne, Alex Murison, Tiago da Silva Medina, et al.. (2019). Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells. Nature Communications. 10(1). 1436–1436. 29 indexed citations

12.

Danis, Etienne, Angela Pierce, Dong Wang, et al.. (2019). Combined functional genomic and chemical screens identify SETD8 as a therapeutic target in MYC-driven medulloblastoma. JCI Insight. 4(1). 16 indexed citations

13.

Mimura, Naoya, Motohiko Oshima, Atsunori Saraya, et al.. (2017). Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition. Clinical Cancer Research. 23(16). 4817–4830. 60 indexed citations

14.

Veschi, Veronica, Zhihui Liu, Ty C. Voss, et al.. (2017). Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma. Cancer Cell. 31(1). 50–63. 72 indexed citations

15.

Beak, Ju Youn, Wei Huang, Joel S. Parker, et al.. (2017). An Oral Selective Alpha-1A Adrenergic Receptor Agonist Prevents Doxorubicin Cardiotoxicity. JACC Basic to Translational Science. 2(1). 39–53. 37 indexed citations

16.

Hassan, Mohamed Abou El, Katherine Huang, Yu Tao, et al.. (2015). Cancer Cells Hijack PRC2 to Modify Multiple Cytokine Pathways. PLoS ONE. 10(6). e0126466–e0126466. 26 indexed citations

17.

Katona, Bryson W., et al.. (2014). EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells. Cancer Biology & Therapy. 15(12). 1677–1687. 42 indexed citations

18.

Ma, Anqi, Wenyu Yu, Fengling Li, et al.. (2014). Discovery of a Selective, Substrate-Competitive Inhibitor of the Lysine Methyltransferase SETD8. Journal of Medicinal Chemistry. 57(15). 6822–6833. 74 indexed citations

19.

Mimura, Naoya, Shuhei Koide, Anqi Ma, et al.. (2014). EZH2 Inhibition and the Combination with Proteasome Inhibition Are Novel Potential Strategies for the Treatment of Multiple Myeloma. Blood. 124(21). 2094–2094. 3 indexed citations

20.

Xu, Bowen, Anqi Ma, Trevor Parton, et al.. (2014). Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood. 125(2). 346–357. 173 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact